Immune-related adverse events as clinical biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors
CONCLUSIONS: We found that ICI-treated mRCC patients who experienced irAEs, particularly thyroid irAEs, had significantly improved clinical outcomes compared to patients who did not have irAEs. This suggests that irAEs may be effective clinical biomarkers in ICI-treated mRCC patients. Future, prospective studies are warranted to validate these findings.IMPLICATIONS FOR PRACTICE: We found that early onset immune-related adverse events (irAEs) are associated with significantly improved clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). In our site-specific ir...
Source: The Oncologist - June 22, 2021 Category: Cancer & Oncology Authors: Dylan J Martini Subir Goyal Yuan Liu Sean T Evans T Anders Olsen Katherine Case Benjamin L Magod Jacqueline T Brown Lauren Yantorni Greta Anne Russler Sarah Caulfield Jamie M Goldman Bassel Nazha Wayne B Harris Haydn T Kissick Viraj A Master Omer Kucuk Br Source Type: research

Neurocognitive Impairment after Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms
Oncologist. 2021 Jun 22. doi: 10.1002/onco.13867. Online ahead of print.ABSTRACTHematopoietic stem cell transplant (HSCT) plays a central role in the treatment of hematologic cancers. With the increasing survival of patients after HSCT, survivorship issues experienced by this population have become an important outcome. Cognitive impairment is an established sequela of HSCT, with studies to date establishing its presence, associated risk factors, and clinical phenotype. There are multiple potential contributors to cognitive impairment post-HSCT. Efforts are ongoing to further characterize its clinical phenotype, associated...
Source: The Oncologist - June 22, 2021 Category: Cancer & Oncology Authors: Rebecca Harrison Noha Sharafeldin Jennie L Rexer Brennan Streck Melissa Petersen Ashley Henneghan Shelli R Kesler Source Type: research

Regarding HER2-amplified Biliary Tract Cancer
Oncologist. 2021 Jun 22. doi: 10.1002/onco.13872. Online ahead of print.NO ABSTRACTPMID:34156737 | DOI:10.1002/onco.13872 (Source: The Oncologist)
Source: The Oncologist - June 22, 2021 Category: Cancer & Oncology Authors: Shubham Pant Source Type: research

The Matilda Effect: Under-recognition of Women in Hematology and Oncology Awards
Oncologist. 2021 Jun 22. doi: 10.1002/onco.13871. Online ahead of print.ABSTRACTBACKGROUND: The proportion of women in the field of hematology and oncology (H&O) has increased over recent decades, but the representation of women in leadership positions remains poor. In an effort to close the gender gap in academia, it is important to report on such inequities in hopes to close these gaps and improve career development.MATERIALS AND METHODS: We conducted a retrospective, observational study of published award recipients from 1994 to 2019 from the seven major H&O societies in the world. Gender was determined based on...
Source: The Oncologist - June 22, 2021 Category: Cancer & Oncology Authors: Shruti R Patel Frederique St Pierre Ana I Velazquez Snegha Ananth Urshila Durani Andrea Anampa-Guzm án Katerina Castillo Natasha Dhawan Amy S Oxentenko Narjust Duma Source Type: research

Identification of somatic gene signatures in circulating cfDNA associated with disease progression in metastatic prostate cancer by a novel machine learning platform
CONCLUSION: These results provide clinical evidence that progression from mCSPC to mCRPC is associated with stereotyped concomitant gain-of-function aberrations in these pathways. Furthermore, detection of these aberrations in cfDNA, may overcome the challenges associated with obtaining tumor bone biopsies, and allow contemporary investigation of combinatorial therapies that target these aberrations.IMPLICATIONS FOR PRACTICE: The progression from castration-sensitive to castration-resistant prostate cancer is characterized by worse prognosis and there is a pressing need for targeted drugs to prevent or delay this transitio...
Source: The Oncologist - June 22, 2021 Category: Cancer & Oncology Authors: Edwin Lin Andrew W Hahn Roberto H Nussenzveig Sergiusz Wesolowski Nicolas Sayegh Benjamin L Maughan Taylor McFarland Nityam Rathi Deepika Sirohi Guru Sonpavde Umang Swami Manish Kohli Thereasa Rich Oliver Sartor Mark Yandell Neeraj Agarwal Source Type: research

Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13866. Online ahead of print.NO ABSTRACTPMID:34152031 | DOI:10.1002/onco.13866 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13863. Online ahead of print.NO ABSTRACTPMID:34152054 | DOI:10.1002/onco.13863 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13864. Online ahead of print.NO ABSTRACTPMID:34152059 | DOI:10.1002/onco.13864 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13865. Online ahead of print.NO ABSTRACTPMID:34152061 | DOI:10.1002/onco.13865 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13866. Online ahead of print.NO ABSTRACTPMID:34152031 | DOI:10.1002/onco.13866 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13863. Online ahead of print.NO ABSTRACTPMID:34152054 | DOI:10.1002/onco.13863 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13864. Online ahead of print.NO ABSTRACTPMID:34152059 | DOI:10.1002/onco.13864 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer
Oncologist. 2021 Jun 21. doi: 10.1002/onco.13865. Online ahead of print.NO ABSTRACTPMID:34152061 | DOI:10.1002/onco.13865 (Source: The Oncologist)
Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research

Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions
Oncologist. 2021 Jun 17. doi: 10.1002/onco.13862. Online ahead of print.NO ABSTRACTPMID:34137481 | DOI:10.1002/onco.13862 (Source: The Oncologist)
Source: The Oncologist - June 17, 2021 Category: Cancer & Oncology Authors: Vrushab Gowda Tendai Kwaramba Cynthia Hanemann Jorge A Garcia Pedro Barata Source Type: research

Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions
Oncologist. 2021 Jun 17. doi: 10.1002/onco.13862. Online ahead of print.NO ABSTRACTPMID:34137481 | DOI:10.1002/onco.13862 (Source: The Oncologist)
Source: The Oncologist - June 17, 2021 Category: Cancer & Oncology Authors: Vrushab Gowda Tendai Kwaramba Cynthia Hanemann Jorge A Garcia Pedro Barata Source Type: research

Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions
Oncologist. 2021 Jun 17. doi: 10.1002/onco.13862. Online ahead of print.NO ABSTRACTPMID:34137481 | DOI:10.1002/onco.13862 (Source: The Oncologist)
Source: The Oncologist - June 17, 2021 Category: Cancer & Oncology Authors: Vrushab Gowda Tendai Kwaramba Cynthia Hanemann Jorge A Garcia Pedro Barata Source Type: research

Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions
Oncologist. 2021 Jun 17. doi: 10.1002/onco.13862. Online ahead of print.NO ABSTRACTPMID:34137481 | DOI:10.1002/onco.13862 (Source: The Oncologist)
Source: The Oncologist - June 17, 2021 Category: Cancer & Oncology Authors: Vrushab Gowda Tendai Kwaramba Cynthia Hanemann Jorge A Garcia Pedro Barata Source Type: research

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Oncologist. 2021 Jun 15. doi: 10.1002/onco.13859. Online ahead of print.ABSTRACTIn June 2020, the FDA granted accelerated approval to selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Approval was based on SADAL, a multicenter trial of selinexor monotherapy in patients with DLBCL after 2 to 5 systemic regimens. Efficacy was based on independent review committee-assessed objective response rate (ORR) and duration of response using Lugano criteri...
Source: The Oncologist - June 16, 2021 Category: Cancer & Oncology Authors: Yvette L Kasamon Lauren S L Price Olanrewaju O Okusanya Nicholas C Richardson Ruo-Jing Li Lian Ma Yu-Te Wu Marc Theoret Richard Pazdur Nicole J Gormley Source Type: research

Impact of COVID-19 infection on cancer patients: experience in Latin American country, ACHOCC-19 Study
Oncologist. 2021 Jun 15. doi: 10.1002/onco.13861. Online ahead of print.ABSTRACTINTRODUCTION: The ACHOCC-19 study was performed to characterize COVID-19 infection in our oncological population.METHODOLOGY: Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression.RES...
Source: The Oncologist - June 16, 2021 Category: Cancer & Oncology Authors: Aylen Vanessa Ospina Ricardo Bruges William Mantilla Iv án Triana Pedro Ramos Sandra Aruachan Alicia Quiroga Isabel Munevar Juan Ortiz N éstor Llinás Paola Pinilla Henry Vargas Henry Idrobo Andrea Russi Ray Manneh Kopp Giovanna Rivas H éctor González Source Type: research

A phase I, first-in-human study of GSK2849330, an anti-HER3 monoclonal antibody, in HER3-expressing solid tumors
CONCLUSION: GSK2849330 demonstrated a favorable safety profile, dose-proportional PK, and evidence of target engagement, but limited anti-tumor activity in HER3-expressing cancers. The exceptional response seen in a patient with CD74-NRG1-rearranged NSCLC suggests further exploration in NRG1-fusion-positive cancers.IMPLICATIONS FOR PRACTICE: This first-in-human study confirms that GSK2849330 is well tolerated. Importantly, across a variety of HER3-expressing advanced tumors, prospective selection by HER3/NRG1 expression alone was insufficient to identify patients who could benefit from treatment with this ADCC- and CDC-enh...
Source: The Oncologist - June 16, 2021 Category: Cancer & Oncology Authors: H K Gan M Millward M Jalving I Garrido-Laguna J D Lickliter J H M Schellens M P Lolkema C Van Herpen B Hug L Tang R O'Connor-Semmes B Gagnon C Ellis G Ganji C Matheny A Drilon Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Liquid biopsy in gliobastoma management: from current research to future perspectives
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13858. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis and predicting outcome of the treatment; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the ris...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Lidia Gatto Enrico Franceschi Vincenzo Di Nunno Alicia Tosoni Raffaele Lodi Alba Ariela Brandes Source Type: research

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Oncologist. 2021 Jun 8. doi: 10.1002/onco.13857. Online ahead of print.ABSTRACTBACKGROUND: Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for refractory mCRC patients.PATIENTS AND METHODS: This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least 2 lines of therapies were 2:1 randomized to receive oral anlotinib (12 mg/day; days 1-14; 21 days/cycle) or placebo, plus be...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).MATERIAL AND METHODS: We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling (CGP) and compared them to 10,772 primary breast carcinomas (not-paired) specimens. For a subset of 16 triple-negative breast carcinoma (TNBC)-brain metastasis (BM) samples, PD-L1 immunohistochemistry was performed concurrently.RESULTS: A total of 733 consecutive BCBMs were analyzed. Compared to primary BCs, BCBMs were enriched for genomic alterations in TP53 (7...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research

It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer
CONCLUSION: There is great interest and need both from patients and providers for tobacco cessation services in the oncology setting tailored for head/neck cancer patients in the context of cancer care.IMPLICATIONS FOR PRACTICE: While the combination of pharmacotherapy and cognitive-behavioral intervention is the standard evidence-based treatment for tobacco dependence, it must be adapted to meet the needs and wants of patients and providers in order to be effective. This study provides an in-depth examination of such needs among head and neck cancer patients and providers in the context of cancer care. Providers and patie...
Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Alexandra B Khodadadi William Carroll Erica L Lee Barbara Hansen Isabel C Scarinci Source Type: research

Causes of Death following non-metastatic Colorectal Cancer Diagnosis in the United States; a population-based analysis
CONCLUSIONS: Following non-metastatic CRC diagnosis, most deaths remain to be secondary to CRC. Other causes including other cancers and cardiovascular disease represent a significant number of deaths especially in the five years following initial CRC diagnosis. Our findings help guide counselling CRC patients regarding future health risks.IMPLICATIONS FOR PRACTICE: • Most common causes of death following non metastatic CRC are heart diseases, other cancers, COPD and cerebrovascular diseases. • Physicians should counsel patients regarding survivorship with cancer-screening and focus on prevention from non-cancer ...
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Ahmed M Afifi Ahmed O Elmehrath Inas A Ruhban Anas M Saad Mohamed M Gad Muneer J Al-Husseini Tanios Bekaii-Saab Mohamad Bassam Sonbol Source Type: research

Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma
CONCLUSION: The addition of dasatinib did not appear to add incremental clinical benefit to FOLFOX in untreated mPC patients.PMID:34101295 | DOI:10.1002/onco.13853 (Source: The Oncologist)
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Thomas J George Azka Ali Yu Wang Ji-Hyun Lee Alison M Ivey David DeRemer Karen C Daily Carmen J Allegra Steven J Hughes Z Hugh Fan Miles E Cameron Andrew R Judge Jose G Trevino Source Type: research

Real-World Clinical Outcomes in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in US Oncology Clinical Practices: Results From SPEAR-Merkel
CONCLUSION: SPEAR-Merkel showed that patients with laMCC or mMCC treated with IO therapies had improved outcomes compared with chemotherapy in clinical practice. The study provides insight on utilization and clinical outcomes associated with newer, more innovative therapies in clinical practice, which may help clinicians understand the variety of newer treatment options for both laMCC and mMCC.IMPLICATIONS FOR PRACTICE, A BRIEF STATEMENT: To our knowledge, SPEAR-Merkel is the first study to evaluate real-world clinical outcomes in patients with locally advanced (laMCC) and metastatic MCC (mMCC) receiving first-line (1L) av...
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Abhijeet Bhanegaonkar Frank X Liu Marley Boyd Nicole Fulcher Ruth Kim Stan Krulewicz Jodi Smith C Lance Cowey Source Type: research

Dexamethasone-sparing regimens with oral NEPA for the prevention of emesis caused by high-dose cisplatin: A randomized non-inferiority study
CONCLUSIONS: A simplified regimen of NEPA plus single-dose DEX offers comparable CINV prevention throughout 5 days post-chemotherapy with the advantage of sparing patients additional doses of DEX in the high emetic risk setting of cisplatin-based chemotherapy.IMPLICATIONS FOR PRACTICE: Dexamethasone (DEX) has traditionally played an integral role in the management of chemotherapy-induced nausea and vomiting (CINV). While generally considered safe, even short-term DEX use is associated with various side effects, and some evidence suggests that steroids may reduce the efficacy of immunotherapies and cellular therapies, if us...
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Luigi Celio Diego Cortinovis Alessio Aligi Cogoni Luigi Cavanna Olga Martelli Simona Carnio Elena Collov à Federica Bertolini Fausto Petrelli Alessandra Cassano Rita Chiari Francesca Zanelli Salvatore Pisconti Isabella Vittimberga Antonietta Letizia Andr Source Type: research

Causes of Death following non-metastatic Colorectal Cancer Diagnosis in the United States; a population-based analysis
CONCLUSIONS: Following non-metastatic CRC diagnosis, most deaths remain to be secondary to CRC. Other causes including other cancers and cardiovascular disease represent a significant number of deaths especially in the five years following initial CRC diagnosis. Our findings help guide counselling CRC patients regarding future health risks.IMPLICATIONS FOR PRACTICE: • Most common causes of death following non metastatic CRC are heart diseases, other cancers, COPD and cerebrovascular diseases. • Physicians should counsel patients regarding survivorship with cancer-screening and focus on prevention from non-cancer ...
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Ahmed M Afifi Ahmed O Elmehrath Inas A Ruhban Anas M Saad Mohamed M Gad Muneer J Al-Husseini Tanios Bekaii-Saab Mohamad Bassam Sonbol Source Type: research

Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma
CONCLUSION: The addition of dasatinib did not appear to add incremental clinical benefit to FOLFOX in untreated mPC patients.PMID:34101295 | DOI:10.1002/onco.13853 (Source: The Oncologist)
Source: The Oncologist - June 8, 2021 Category: Cancer & Oncology Authors: Thomas J George Azka Ali Yu Wang Ji-Hyun Lee Alison M Ivey David DeRemer Karen C Daily Carmen J Allegra Steven J Hughes Z Hugh Fan Miles E Cameron Andrew R Judge Jose G Trevino Source Type: research